A scientifically proven Microbiome immunotherapy for the treatment of colorectal cancer

Informazioni relative al progetto

Oncarin

ID dell’accordo di sovvenzione: 812776

DOI

10.3030/812776

Progetto chiuso

Data della firma CE 27 Aprile 2018

Data di avvio 1 Maggio 2018

Data di completamento 31 Agosto 2018

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

Z.M.D MEDICAL LTD
Israel

Periodic Reporting for period 1 - Oncarin (A scientifically proven Microbiome immunotherapy for the treatment of colorectal cancer)

Periodo di rendicontazione: 2018-05-01 al 2018-08-31

Sintesi del contesto e degli obiettivi generali del progetto

Following 30 years of research, Z.M.D medial ltd (Z.M.D) has developed Oncarin; a breakthrough Microbiome therapeutic remedy to cure the cause of colorectal cancer, which is a common malignancy with a 5-year survival less than 60%. The core technology of Oncarin is based on specific bacteria strains with high oncolytic activity, which are part of the natural microflora of a healthy individual. If the immune system is weakened, cancer cells are not eliminated resulting in tumor growth. Oncarin empowers the human body to naturally kill cancer cells by enhancing its own immune defence, causing no pain or side effects. In addition, Oncarin can be easily implemented for a wide range of immune conditions including cancer, Crohn’s disease, colitis and immune system disorders after long-term treatment with antibiotics. Moreover, Oncarin costs 90% less in comparison to current solutions. This will improve patient outcomes and greatly reduce healthcare costs. The aim of this project was to examine the technical and commercial feasibility of Oncarin and based on the results Z.M.D has set a goal to bring Oncarin to the market.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

The feasibility of Oncarin was assessed by consulting with pharmaceutical companies and regulatory experts and the delivery of a market research and business plan. Based on the information available to us, there appear to be no direct competitors to Z.M.D. in the market today. Despite numerous articles and published researches connecting cancer and bacteria, we did not discover other companies commercializing such treatment. The development of bacterial preparations in treating cancer is at very early stages, whereas Z.M.D is currently leading the field.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Oncarin now has a TRL 6, since successfully completing proof of concept in animal models. We have planned a final pre-clinical experiment prior to conducting a phase I trial in order to demonstrate safety and pharmacokinetics of Oncarin. The Z.M.D business model is based on the advantage of joining with strategic partner for support for advanced clinical phases and product distribution. The global distribution rights of Oncarin are anticipated on the basis of a Milestones Agreement with the selected partner. On completion of successful pre-clinical trials, and while entering first-in-human trials, Z.M.D will consider the option of going public with a listing perhaps on NASDAQ.

Logo Oncarin